{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-001796","form_type":"8-K","ticker":"BDPT","cik":"0001575142","company_name":"BIOADAPTIVES, INC.","filed_at":"2024-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.842778+00:00","generated_at":"2026-05-29T14:09:11.603380+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioAdaptives gets IRB approval for human trial of weight management product Zeranovia","bullets":["IRB approved human clinical trial for Zeranovia, a weight management supplement.","First phase to confirm dosing and identify side effects; participant slots quickly filled.","CEO notes less than 1% of nutraceuticals undergo human trials; aims for scientific proof.","Trial managed by doctors in Las Vegas, NV; next stage open to more participants.","If successful, Zeranovia could compare favorably to synthetic GLP-1 and GIP treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-001796","json":"https://secwatch.observer/filing/0001640334-24-001796.json","markdown":"https://secwatch.observer/filing/0001640334-24-001796.md","text":"https://secwatch.observer/filing/0001640334-24-001796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1575142/000164033424001796/0001640334-24-001796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1575142/000164033424001796/bdpt_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T14:09:11.603380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}